NXTC

Nextcure Inc

Stock NASDAQ – Stock Market Prices, News & Analysis

Nextcure is a biopharmaceutical company focused on the discovery and development of novel immunotherapies for the treatment of cancer.

$ 11.02
11.13 %

Nextcure Inc

$ 11.02
11.13 %
NXTC

Nextcure is a biopharmaceutical company focused on the discovery and development of novel immunotherapies for the treatment of cancer.

Price history of Nextcure Inc
Price history of Nextcure Inc

Performance & Momentum

6 Months 19.78 %
1 Year 119.17 %
3 Years 41.32 %
5 Years 89.53 %

Strategic Analysis

Nextcure Inc • 2026

Nextcure is positioned as an innovative player in biotechnology, specializing in the development of anticancer immunotherapies. Its model is based on advanced research into targeted therapies to address significant medical needs in cancer, a high-value sector with sustained growth.

Strengths
  • Strong expertise in immuno-oncology, a field with high therapeutic and commercial potential
  • Promising clinical progress that could accelerate re-rating during validation phases
  • Positioning in a favorable market supported by growing demand for alternatives to traditional treatments
Weaknesses
  • Long-term performance history marked by significant volatility and substantial losses
  • Lack of recent news, suggesting a possible need for additional catalysts to support the share price
Momentum

Current momentum, which has been relatively strong over the past six months, reflects renewed investor interest, likely linked to recent clinical progress. This positive trend warrants cautious optimism, but the absence of strong signals over the past year suggests remaining prudent about the durability of this trajectory.

Similar stocks to Nextcure Inc

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone